Stock Alert: Lexicon Pharmaceuticals Surges 35%

(RTTNews) - Shares of Lexicon Pharmaceuticals, Inc. (LXRX) are currently gaining over 35% after the company said it received a regulatory feedback that clears a key hurdle for partnership discussions around sotagliflozin in heart failure.

LXRX is currently trading at $5.33, up $1.41 or 35.97%, on the Nasdaq.

Lexicon Pharmaceuticals said it received U.S. Food and Drug Administration regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.